Sanofi SA

1SAN

Company Profile

  • Business description

    Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

  • Contact

    46, Avenue de la Great Army
    Paris75017
    FRA

    T: +33 153774000

    E: [email protected]

    https://www.sanofi.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    82,878

Stocks News & Analysis

stocks

Is this ASX share a long-term buy?

Current operating conditions are challenging but over the long-term prospects are better.
stocks

Why Guzman and Reece's share reversals have a lot in common

Investors must weigh exciting growth stories against competitive dynamics and the price they are being asked to pay.
stocks

Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?

Watching the data centre business and the debate around it, here’s what we think of Nvidia stock.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,477.3020.70-0.24%
CAC 408,143.9292.851.15%
DAX 4022,794.11383.841.71%
Dow JONES (US)43,411.6849.53-0.11%
FTSE 1008,706.5937.920.44%
HKSE23,787.93753.913.27%
NASDAQ19,035.388.990.05%
Nikkei 22538,142.3795.42-0.25%
NZX 50 Index12,452.46145.191.18%
S&P 5005,948.966.29-0.11%
S&P/ASX 2008,240.7011.20-0.14%
SSE Composite Index3,380.2134.171.02%

Market Movers